REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND COSTS FOLLOWING MAVACAMTEN INITIATION IN US PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Author(s)
Jyotirmoy Sarker, PhD1, Michael Pham, MS, PharmD2, Aaron N. Winn, MPP, PhD3.
1Research Assistant Professor, University of Mississippi, University, MS, USA, 2University of Illinois at Chicago Department of Pharmacy Systems, Outcomes, and Policy, Chicago, IL, USA, 3University of Illinois at Chicago, Chicago, IL, USA.
1Research Assistant Professor, University of Mississippi, University, MS, USA, 2University of Illinois at Chicago Department of Pharmacy Systems, Outcomes, and Policy, Chicago, IL, USA, 3University of Illinois at Chicago, Chicago, IL, USA.
OBJECTIVES: Mavacamten, a first-in-class cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (HCM), has demonstrated clinical efficacy in trials. Its real-world impact on healthcare resource utilization (HCRU) and costs remains unclear. We characterized HCRU and costs among mavacamten-treated HCM patients before and after initiation using US claims data.
METHODS: We used the Merative MarketScan Commercial Claims and Medicare Supplemental databases to conduct a single-group pre-post retrospective analysis. Eligible patients initiated mavacamten between April 28, 2022, and September 30, 2024, and had ≥365 days of continuous enrollment before mavacamten initiation. Follow-up extended from initiation until disenrollment or December 31, 2024. HCRU and costs were expressed as per-patient-per-month (PPPM) rates during the 365-day pre-index baseline period and variable follow-up. Pre-post changes were assessed using paired statistical tests.
RESULTS: A total of 282 patients were included (mean age 58.1 years [SD 12.0]; 51.4% male; mean follow-up 348.5 days [SD 201.6]). Hypertension was present in 70.9% and heart failure in 31.2%; 85.1% used beta-blockers at baseline. After mavacamten initiation, all-cause outpatient visits increased from 2.44 to 2.72 PPPM (p<0.001) and HCM-related outpatient visits from 0.63 to 0.95 PPPM (p<0.001), consistent with increased cardiac monitoring. The proportion with any hospitalization decreased from 17.4% to 11.3% (p=0.024). Mean total healthcare costs increased from $1,508 to $9,549 PPPM (p<0.001), primarily driven by mavacamten drug costs ($7,890 PPPM; p<0.001). After excluding mavacamten drug costs, total healthcare expenditures remained stable across time-stratified follow-up periods ($1,640, $1,773, and $1,209 PPPM at 0-6, 7-12, and 12+ months, respectively) and were comparable to the pre-index baseline ($1,508 PPPM).
CONCLUSIONS: Mavacamten initiation was associated with increased outpatient monitoring, lower hospitalization rates, and no significant increase in non-drug healthcare costs. The overall cost increase was driven primarily by mavacamten drug expenditures. These findings provide real-world context for economic evaluations of mavacamten in obstructive HCM.
METHODS: We used the Merative MarketScan Commercial Claims and Medicare Supplemental databases to conduct a single-group pre-post retrospective analysis. Eligible patients initiated mavacamten between April 28, 2022, and September 30, 2024, and had ≥365 days of continuous enrollment before mavacamten initiation. Follow-up extended from initiation until disenrollment or December 31, 2024. HCRU and costs were expressed as per-patient-per-month (PPPM) rates during the 365-day pre-index baseline period and variable follow-up. Pre-post changes were assessed using paired statistical tests.
RESULTS: A total of 282 patients were included (mean age 58.1 years [SD 12.0]; 51.4% male; mean follow-up 348.5 days [SD 201.6]). Hypertension was present in 70.9% and heart failure in 31.2%; 85.1% used beta-blockers at baseline. After mavacamten initiation, all-cause outpatient visits increased from 2.44 to 2.72 PPPM (p<0.001) and HCM-related outpatient visits from 0.63 to 0.95 PPPM (p<0.001), consistent with increased cardiac monitoring. The proportion with any hospitalization decreased from 17.4% to 11.3% (p=0.024). Mean total healthcare costs increased from $1,508 to $9,549 PPPM (p<0.001), primarily driven by mavacamten drug costs ($7,890 PPPM; p<0.001). After excluding mavacamten drug costs, total healthcare expenditures remained stable across time-stratified follow-up periods ($1,640, $1,773, and $1,209 PPPM at 0-6, 7-12, and 12+ months, respectively) and were comparable to the pre-index baseline ($1,508 PPPM).
CONCLUSIONS: Mavacamten initiation was associated with increased outpatient monitoring, lower hospitalization rates, and no significant increase in non-drug healthcare costs. The overall cost increase was driven primarily by mavacamten drug expenditures. These findings provide real-world context for economic evaluations of mavacamten in obstructive HCM.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD122
Topic
Economic Evaluation, Real World Data & Information Systems
Disease
Gastrointestinal Disorders